Despite the almost ubiquitous need for intravenous fluids in acutely ill patients, there has been little consensus on the most appropriate rate of administration and composition of intravenous fluids, ...
STOCKHOLM, Sweden, Jan. 26, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing Authorisation Variation to ...
Modeling simulations predict that transitioning to once every 4 weeks of lecanemab after 18 months will maintain clinical and biomarker therapy benefits. The Food and Drug Administration (FDA) has ...
The management of intravenous fluids in paediatrics remains a critical component of care in both routine and acute settings. Intravenous fluid therapy is not only essential for hydration and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results